Bristol-Myers claims the lead in a race to develop a TYK2 drug, hoping to disrupt a huge market for anti-inflammatories
Bristol-Myers Squibb’s TYK2 team has been showing off some Phase II data they believe puts them in the running for leader of a small but …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
